Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Treatment-Naïve PD-L1”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Study completedNCT03697304
What this trial is testing

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Who this might be right for
Neoplasm MetastasisAdvanced TumorsMetastatic Solid Tumors
Boehringer Ingelheim 211
Large-scale testing (Phase 3)Active Not RecruitingNCT05215340
What this trial is testing

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo 740
Testing effectiveness (Phase 2)Looking for participantsNCT06892548
What this trial is testing

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Who this might be right for
Advanced Lung Cancer
BioNTech SE 594
Testing effectiveness (Phase 2)Study completedNCT04165083
What this trial is testing

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 102
Testing effectiveness (Phase 2)Study completedNCT05342636
What this trial is testing

Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Merck Sharp & Dohme LLC 90
Large-scale testing (Phase 3)Active Not RecruitingNCT05785767
What this trial is testing

Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals 149
Testing effectiveness (Phase 2)Study completedNCT04993677
What this trial is testing

SEA-CD40 Given With Other Drugs in Cancers

Who this might be right for
MelanomaCarcinoma, Non-Small- Cell Lung
Seagen Inc. 77
Large-scale testing (Phase 3)Study completedNCT02220894
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 1,274
Not applicableLooking for participantsNCT06988592
What this trial is testing

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Who this might be right for
Advanced Biliary Tract Cancer
Fudan University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05557591
What this trial is testing

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals 51
Large-scale testing (Phase 3)Study completedNCT03850444
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 262
Testing effectiveness (Phase 2)Ended earlyNCT04925986
What this trial is testing

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung DiseasesLung Neoplasms+6 more
Sarah Goldberg 9